The Cytosponge has yet to be validated for the surveillance of BE patients; however, several pilot studies have been carried out showing that the Cytosponge-TFF3 could enable targeted endoscopy for higher-risk individuals [43,44], with TFF3 positivity increasing with segment length (odds ratio 1.37 per 1 cm segment length), while those BE patients with TFF3-negative sponge results and short segments could potentially be saved endoscopic surveillance. The gene discussed is TFF3; the disease is Barrett esophagus.